Ref21C13
Therapeutic and Antilipoperoxidant
Effects of Silibyn-Phosphatidylcholine Complex (Siliphos®) in
Chronic Liver Disease:
Preliminary Results
S. Moscarella1, A. Giusti1, F. Marra1, C. Marena2, M. Lampertico2, P. Relli1,
P. Gentilini1 and G. Buzzelli1
1. Institute of Clinica Medica II, University of Florence, Florence, Italy and
2. Medical
Department, Inverna della Beffa, Milan, Italy
Journal not listed on Medline
Eight patients (two men and six women), with viral chronic
active hepatitis were
treated with (Siliphos®) for two months.
After treatment, serum malondialdehyde
levels decreased by 36% (which indicates significantly less liver damage) and
the quantitiative liver function evaluation increased by 15% (which is quite
dramatic).
A statistically significant reduction of transaminases was also
seen.
These results indicate (Siliphos®) is effective in improving the biochemical
and quantitative indices of hepatic function in patients with chronic active
hepatitis.
|